Actinium Pharmaceuticals Inc
ATNM1.705USD
+0.115+7.23%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
53.19MMarket Cap
LossP/E TTM
More Details of Actinium Pharmaceuticals Inc Company
Actinium Pharmaceuticals, Inc. specializes in the development of targeted radiotherapies. The Company is advancing its lead product candidate Actimab-A, a CD33 targeting therapeutic, as potential backbone therapy in acute myeloid leukemia (AML) and other myeloid malignancies leveraging the mutation agnostic alpha-emitter radioisotope payload Actinium-225 (Ac-225). The Company is engaged with the National Cancer Institute (NCI) under the Cooperative Research and Development Agreement (CRADA) for development of Actimab-A in AML and other myeloid malignancies. ATNM-400 is the Company's novel non-PSMA targeting Ac-225 radiotherapy for prostate cancer. Iomab-ACT, its conditioning candidate, is being developed to improve patient access and outcomes for potentially curative cell and gene therapies. Its Iomab-B program is an induction and conditioning agent prior to bone marrow transplant in patients with r/r AML, which it is seeking a potential strategic partner for the United States.
Actinium Pharmaceuticals Inc Info
Ticker SymbolATNM
Company nameActinium Pharmaceuticals Inc
IPO dateMar 26, 2014
CEOSeth (Sandesh)
Number of employees37
Security typeOrdinary Share
Fiscal year-endMar 26
Address100 Park Ave., 23Rd Floor
CityNEW YORK
Stock exchangeNASDAQ OMX – NASDAQ Basic Amex
CountryUnited States of America
Postal code10017
Phone16466773870
Websitehttps://www.actiniumpharma.com/
Ticker SymbolATNM
IPO dateMar 26, 2014
CEOSeth (Sandesh)
Company Executives of Actinium Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Sandesh (Andes) Seth
Mr. Sandesh (Andes) Seth
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
184.48K
+3328.38%
Dr. Ajit S. Shetty, Ph.D.
Dr. Ajit S. Shetty, Ph.D.
Independent Director
Independent Director
757.00
--
Mr. Richard I. Steinhart
Mr. Richard I. Steinhart
Independent Director
Independent Director
316.00
--
Mr. Steve O'Loughlin
Mr. Steve O'Loughlin
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
--
--
Dr. June S. Almenoff, M.D., Ph.D.
Dr. June S. Almenoff, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Jeffrey W. Chell, M.D.
Dr. Jeffrey W. Chell, M.D.
Independent Director
Independent Director
--
--
Dr. C. David Nicholson, Ph.D.
Dr. C. David Nicholson, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Sandesh (Andes) Seth
Mr. Sandesh (Andes) Seth
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
184.48K
+3328.38%
Dr. Ajit S. Shetty, Ph.D.
Dr. Ajit S. Shetty, Ph.D.
Independent Director
Independent Director
757.00
--
Mr. Richard I. Steinhart
Mr. Richard I. Steinhart
Independent Director
Independent Director
316.00
--
Mr. Steve O'Loughlin
Mr. Steve O'Loughlin
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
--
--
Dr. June S. Almenoff, M.D., Ph.D.
Dr. June S. Almenoff, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Jeffrey W. Chell, M.D.
Dr. Jeffrey W. Chell, M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
FY2024
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
4.44%
District 2 Capital LP
2.47%
Millennium Management LLC
2.00%
Acadian Asset Management LLC
1.57%
Bigger (Michael)
1.44%
Other
88.08%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
4.44%
District 2 Capital LP
2.47%
Millennium Management LLC
2.00%
Acadian Asset Management LLC
1.57%
Bigger (Michael)
1.44%
Other
88.08%
Shareholder Types
Shareholders
Proportion
Hedge Fund
8.05%
Investment Advisor
7.04%
Investment Advisor/Hedge Fund
4.15%
Individual Investor
2.36%
Research Firm
0.48%
Family Office
0.08%
Venture Capital
0.06%
Other
77.78%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
183
6.17M
30.73%
--
2025Q3
188
6.17M
30.79%
-316.72K
2025Q2
191
6.49M
36.64%
-2.83M
2025Q1
192
9.33M
38.12%
-2.56M
2024Q4
194
9.27M
38.27%
-591.25K
2024Q3
185
9.83M
32.22%
+1.01M
2024Q2
171
8.81M
31.57%
+497.32K
2024Q1
162
8.31M
28.24%
+7.70K
2023Q4
162
7.24M
32.39%
+143.09K
2023Q3
163
7.09M
31.30%
-112.93K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
1.37M
4.4%
-199.92K
-12.72%
Jun 30, 2025
District 2 Capital LP
769.45K
2.47%
-56.98K
-6.89%
Nov 08, 2024
Millennium Management LLC
663.27K
2.13%
+663.27K
--
Jun 30, 2025
Acadian Asset Management LLC
491.94K
1.58%
-12.10K
-2.40%
Jun 30, 2025
Bigger (Michael)
450.17K
1.44%
-27.50K
-5.76%
Nov 08, 2024
BlackRock Institutional Trust Company, N.A.
450.74K
1.44%
-1.34M
-74.80%
Jun 30, 2025
Geode Capital Management, L.L.C.
329.69K
1.06%
-382.11K
-53.68%
Jun 30, 2025
Renaissance Technologies LLC
209.50K
0.67%
+151.90K
+263.72%
Jun 30, 2025
Bigger Capital Funds, LP
235.69K
0.76%
-205.41K
-46.57%
Nov 08, 2024
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.01%
iShares Russell 2000 ETF
0%
iShares Russell 2000 Growth ETF
0%
ProShares UltraPro Russell2000
0%
Global X Russell 2000 Covered Call ETF
0%
ProShares Hedge Replication ETF
0%
Avantis US Small Cap Equity ETF
0%
Global X Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
iShares Russell 2000 Value ETF
0%
iShares Micro-Cap ETF
Proportion0.01%
iShares Russell 2000 ETF
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
Global X Russell 2000 Covered Call ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Aug 10, 2020
Merger
30→1
Aug 10, 2020
Merger
30→1
Aug 10, 2020
Merger
30→1
Aug 10, 2020
Merger
30→1
Date
Type
Ratio
Aug 10, 2020
Merger
30→1
Aug 10, 2020
Merger
30→1
Aug 10, 2020
Merger
30→1
Aug 10, 2020
Merger
30→1
FAQs
Who are the top five shareholders of Actinium Pharmaceuticals Inc?
The top five shareholders of Actinium Pharmaceuticals Inc are:
The Vanguard Group, Inc. holds 1.37M shares, accounting for 4.40% of the total shares.
District 2 Capital LP holds 769.45K shares, accounting for 2.47% of the total shares.
Millennium Management LLC holds 663.27K shares, accounting for 2.13% of the total shares.
Acadian Asset Management LLC holds 491.94K shares, accounting for 1.58% of the total shares.
Bigger (Michael) holds 450.17K shares, accounting for 1.44% of the total shares.
The Vanguard Group, Inc. holds 1.37M shares, accounting for 4.40% of the total shares.
District 2 Capital LP holds 769.45K shares, accounting for 2.47% of the total shares.
Millennium Management LLC holds 663.27K shares, accounting for 2.13% of the total shares.
Acadian Asset Management LLC holds 491.94K shares, accounting for 1.58% of the total shares.
Bigger (Michael) holds 450.17K shares, accounting for 1.44% of the total shares.
What are the top three shareholder types of Actinium Pharmaceuticals Inc?
The top three shareholder types of Actinium Pharmaceuticals Inc are:
The Vanguard Group, Inc.
District 2 Capital LP
Millennium Management LLC
The Vanguard Group, Inc.
District 2 Capital LP
Millennium Management LLC
How many institutions hold shares of Actinium Pharmaceuticals Inc (ATNM)?
As of 2025Q4, 183 institutions hold shares of Actinium Pharmaceuticals Inc, with a combined market value of approximately 6.17M, accounting for 30.73% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.06%.
What is the biggest source of revenue for Actinium Pharmaceuticals Inc?
In FY2024, the -- business generated the highest revenue for Actinium Pharmaceuticals Inc, amounting to -- and accounting for --% of total revenue.
